Fresenius Medical Care AG & Co. KGaA (ETR: FME)‘s stock had its “add” rating reaffirmed by AlphaValue in a research note issued on Thursday. They currently have a $78.65 (€58) price target on the stock.

FME has been the subject of a number of other recent research reports. Analysts at Sanford C. Bernstein reiterated an “outperform” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note to investors on Monday. They now have a $83.11 price target on the stock. Separately, analysts at Bankhaus Metzler reiterated a “buy” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note to investors on Friday, January 25th. They now have a $82.67 price target on the stock. Finally, analysts at Commerzbank Corporates & Markets reiterated a “hold” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note to investors on Wednesday, January 16th. They now have a $72.00 price target on the stock.

Shares of Fresenius Medical Care AG & Co. KGaA traded down 0.73% during mid-day trading on Thursday, hitting €52.00. Fresenius Medical Care AG & Co. KGaA has a one year low of €47.982 and a one year high of €60.24. The stock’s 50-day moving average is currently €56.72.

Fresenius Medical Care AG & Co KGaA is a Germany-based holding and kidney dialysis company, operating in the fields of dialysis products and dialysis services.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.